GLP

A new University of California study suggests popular GLP-1 weight loss drugs may slow biological aging, not just promote weight loss. Researchers found signs the medications affect aging-related processes in the body, potentially offering health benefits beyond diabetes and obesity treatment. The findings have drawn broad attention, as millions already take GLP-1 drugs and scientists are still mapping their wider long-term effects.

Novo Nordisk and Eli Lilly presented findings at the Aging Research and Drug Discovery (ARDD) meeting suggesting their GLP-1 drugs may slow biological aging, beyond their established effects on diabetes and weight loss. The reports fuel ongoing debate about whether drugs like Ozempic and Mounjaro could double as longevity treatments, and what the evidence actually shows.